Compare Abbott Laboratories (ABT) vs VNET Group Inc (VNET) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs VNET Group Inc — how do they compare? Abbott Laboratories trades at $95.76 (market cap $166.94B), while VNET Group Inc trades at $8.3 (market cap $2.19B). The key difference: Abbott Laboratories is far larger — about 76.2× VNET Group Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals.
| ABT | VNET | |
|---|---|---|
Market Cap | $166.94B | $2.19B |
Sector | Health | Technology |
52-Week High | $136.62 | $14.03 |
52-Week Low | $82.57 | $6.97 |
Enterprise Value | $193.69B | $5.32B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
VNET trades at $7.81, down 1.39% today, amid bearish technical signals and recent earnings misses. The stock shows negative profitability with a -21.63% net income margin and -43.21% ROE for 2025, though revenue reached $9.95B. Analyst sentiment remains positive with 62.5% buy ratings, pointing to a 54% upside target. Recent news highlights strategic AI investments and leadership changes, while a class action settlement adds legal overhang.
The outlook is mixed: strong revenue growth and AI demand offer upside, but persistent losses and high debt pose risks. Investors should weigh analyst optimism against fundamental weaknesses and legal uncertainties before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
